The basal ganglia in Parkinson's disease: Current concepts and unexplained observations

Annals of Neurology

Volumn 64, Issue SUPPL. 2, 2008, Pages

  Obeso, Jose A ^a,b   Marin, Concepcio ^b,c   Rodriguez Oroz, C ^a,b   Blesa, Javier ^a,b   Benitez Temino B ^a   Mena Segovia, Juan ^d   Rodríguez, Manuel ^b,e   Olanow, C Warren ^f  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSIDAD DE LA LAGUNA   (Spain)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; DOPAMINE; LEVODOPA; RASAGILINE;

BASAL GANGLION; CATECHOLAMINE DEPLETION; GLOBUS PALLIDUS; HUMAN; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

ANIMALS; BASAL GANGLIA; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; ELECTRIC STIMULATION THERAPY; HUMANS; NEURAL PATHWAYS; PARKINSON DISEASE;

EID: 58349115847     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21481     Document Type: Review

References (162)

1. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375.
2. Crossman AR. Primate models of dyskinesias: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience 1987;21:1-40.
3. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285.
4. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-381.
5. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990;13:266-271.
6. Middleton FA, Strick PL. Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Res Rev 2000;31:236-250.
7. Buhusi CV, Meck WH. What makes us tick? Functional and neural mechanisms of interval timing. Nat Neurosci Rev 2005;6:755-765.
8. Hikosaka O, Nakamura K, Sakai K, et al. Central mechanisms of motor learning. Curr Opin Neurobiol 2002;12:217-222.
9. Yin HH, Knowlton B. The role of the basal ganglia in habit formation. Nat Neurosci Rev 2006;7:464-476.
10. Obeso JA, Guridi J, DeLong MR. Surgery for Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:2-8.
11. Olanow CW. Pallidotomy: have we made a dent in Parkinson's disease? Ann Neurol 1996;40:341-343.
12. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990;249:1436-1438.
13. Aziz TZ, Peggs D, Sambrook MA, et al. Lesions of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl, 1, 2, 3, 6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord 1991;6:288-292.
14. Guridi J, Herrero MT, Luquin MR, et al. Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. Brain 1996;119:1717-1727.
15. Obeso JA, Rodríguez MC, DeLong MD. Basal ganglia pathophysiology: a critical review. Adv Neurol 1997;73:3-18.
16. Obeso JA, Rodríguez-Oroz MC, Rodríguez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000;23(suppl):S8-S19.
17. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with current model. Ann Neurol 2000;47(suppl 1):22-32.
18. Montgomery EB. Basal ganglia physiology and pathophysiology: a reappraisal. Parkinsonism Relat Disord 2007;13:455-465.
19. Wilson CJ. Basal ganglia. In: Sphepherd GM, ed. The synaptic organization of the brain. Oxford: Oxford University Press, 2004:361-414.
20. Bamford NS, Robinson S, Palmiter R, et al. Dopamine modulates release from corticostriatal terminals. J Neurosci 2004;24:9541-9552.
21. Takada M, Tokuno H, Nambu A, et al. Corticostriatal projections from the somatic areas of the frontal cortex in the macaque monkey: segregation versus overlap of input zones from the primary motor cortex, the supplementary motor area, and the promotor cortex. Exp Brain Res 1998;120:114-128.
22. DeLong MR, Crutcher MD, Georgopoulos AP. Primate globus pallidus and subthalamic nucleus functional organization. J Neurophysiol 1985;53:530-543.
23. Miyahi S, Lu X, Imanishi M, et al. Somatotopically arranged inputs from putamen and subthalamic nucleus to primary motor cortex. Neurosci Res 2006;56:300-308.
24. Lee FJ, Wang YT, Liu F. Direct receptor cross-talk can mediate the modulation of excitatory and inhibitory neurotransmission by dopamine. J Mol Neurosci 2005;26:245-252.
25. Lei W, Jiao Y, Del Mar N, et al. Evidence for differential cortical input to direct pathway versus indirect pathway striatal projection neurons in rats. J Neurosci 2004;24:8289-8299.
26. Onn SP, West AR, Grace AA. Dopamine-mediated regulation of striatal neuronal and network interactions. Trends Neurosci 2000;23(suppl):48-56.
27. West AR, Grace AA. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J Neurosci 2002;22:294-304.
28. Hernandez-Lopez S, Bargas J, Sumeier DJ, et al. D1 receptor activation enhances evoked discharge in neostriatal medium spiny neurons by modulating an L-type Ca2+ conductance. J Neurosci 1997;17:3334-3342.
29. Rodriguez M, Morales I, Gomez I, et al. Heterogeneous dopamine neurochemistry in the striatum: the fountain-drain matrix. J Pharmacol Exp Ther 2006;319:31-43
30. McHaffie JG, Stanford TR, Stein BE, et al. Subcortical loops through the basal ganglia. Trends Neurosci 2005;28:401-407.
31. Wang Z, Kai L, Dopaminey M, et al. Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 2006;50:443-452.
32. Morris G, Arkadir D, Nevet A, et al. Coincident but distinct messages of midbrain dopamine and striatal tonically active neurons. Neuron 2004;43:133-143.
33. Calabresi P, Centonze D, Bubellini P, et al. Acetylcholine-mediated modulation of striatal funtion. Trends Neurosci 2000;23:120-126.
34. Pakhotin P, Bracci E. Cholinergic interneurons control the excitatory input to the striatum. J Neurosci 2007;27:391-400.
35. Tepper MJ, Koós T, Wilson CJ. GABAergic microcircuits in the neostriatum. Trends Neurosci 2004;27:662-669.
36. Bracci E, Centonze D, Bernardi G, Calabresi P. Dopamine excites fast-spiking interneurons in the striatum. J Neurophysiol 2002;87:2190-2194.
37. Centonze D, Grande C, Usiello, et al. Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci 2003;23:6245-6254.
38. Bamford NS, Zhang H, Schmitz Y, et al. Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron 2004;42:653-663.
39. Cho H, Duke D, Manzino L, et al. Dopamine depletion causes fragmented clustering of neurons in the sensorimotor striatum: evidence of lasting reorganization of corticostriatal input. J Comp Neurol 2002;452:24-37.
40. Mallet N, Ballion B, Le Moine C, Gonon F. Cortical inputs and GABA interneurons imbalance projection neurons in the striatum of parkinsonian rats. Neurobiol Dis 2006;26:3875-3884.
41. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007;445:643-647.
42. Morissette M, Grondin R, Goulet M, et al. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J Neurochem 1999;72:682-692.
43. Marin C, Aguilar E, Mengod G, et al. Concomitant short- and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study. Eur J Neurosci 2007;25:259-269.
44. Betarbet R, Greenamyre JT. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. Exp Neurol 2004;189:393-403.
45. Herrero MT, Augood SJ, Asensi H, et al. Effects of l-dopa therapy on dopamine D-2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys. Mol Brain Res 1996;42:149-155.
46. Soghomonian JJ, Chesselet MF. Effects of nigrostriatal lesions on the levels of messenger RNAs encoding two isoforms of glutamate decarboxylase in the globus pallidus and entopeduncular nucleus of the rat. Synapse 1992;11:124-133.
47. Carta AR, Pinna A, Cauli O, et al. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic intermittent L-Dopa and A2A receptor blockade plus L-Dopa in dopamine-denervated rats. Synapse 2002;44:166-174.
48. Katz J, Nielsen KN, Soghomonian JJ. Comparative effects of acute or chronic administration of levodopa to 6-hydroxydopamine-lesioned rats on the expression of glutamic acid decarboxylase in the neostriatum and GABA-A receptors subunits in the substantia nigra, pars reticulata. Neuroscience 2005;132:833-842.
49. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidopaminel neurons. Science 1990;250:1429-1432.
50. Herrero MT, Augood SJ, Hirsch EC, et al. Effects of L-Dopa on prepronekephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 1995;68:1189-1198.
51. Calabresi P, Maj R, Pisani A, et al. Long-term synaptic depression in the striatum: physiological and pharmacological characterization. J Neurosci 1992;12:4224-4233.
52. Calabresi P, Pisani A, Mercuri NB, Bernardi G. Long-term potentiation in the striatum is unmasked by removing the voltage-dependent magnesium block of NMDA receptor channels. Eur J Neurosci 1992;4:929-935.
53. Fino E, Glowinski J, Venance L. Bidirectional activity-dependent plasticity at corticostriatal synapses. J Neurosci 2005;25:11279-11287.
54. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-Dopa-induced dyskinesia. Nat Neurosci 2003;6:501-506.
55. Day M, Wang Z, Ding J, et al. Selective elimination of glutamatergic synapses on striatopallidopaminel neurons in Parkinson disease models. Nat Neurosci 2006;9:251-259.
56. Stephens B, Mueller AJ, Shering AF, et al. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 2005;132:741-754.
57. Fino E, Glowinski J, Venance L. Effects of acute dopamine depletion on the electrophysiological properties of striatal neurons. Neurosci Res 2007;58:305-316.
58. Pisani A, Bonsi P, Centonze D, et al. Activation of D2-like dopaminergic receptors reduces synaptic inputs to striatal cholinergic interneurons. J Neurosci 2000;20:RC69.
59. Raz A, Frechter-Mazar V, Feingold A, et al. Activity of pallidal and striatal tonically active neurons is correlated in mptp-treated monkeys but not in normal monkeys. J Neurosci 2001;21:128.
60. Aosaki T, Kimura M, Graybiel AM. Temporal and spatial characteristics of tonically active neurons of the primate's striatum. J Neurophysiol 1995;73:1234-1252.
61. Nambu A, Takadopamine M, Inase M, Tokuno H. Dual somatotopical representations in the primate subthalamic nucleus: evidence for ordered but reversed body-map transformations from the primary motor cortex and the supplementary motor area. J Neurosci 1996;16:2671-2683.
62. Wichmann T, Bergman H, DeLong MR. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J Neurophysiol 1994;72:521-530.
63. Nambu A, Tokuno H, Hamadopamine I, et al. Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey. J Neurophysiol 2000;84:289-300.
64. DeLong MR, Crutcher MD, Georgopoulos AP. Primate globus pallidus and subthalamic nucleus functional organization. J Neurophysiol 1985;53:530-543.
65. Rodriguez-Oroz MC, Rodriguez M, Guridi J, et al. The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics. Brain 2001;124:1777-1790.
66. Paradiso G, Saint-Cyr JA, Lozano AM, et al. Involvement of the human subthalamic nucleus in movement preparation. Neurology 2003;61:1538-1545.
67. Alegre M, Alonso-Frech F, Rodriguez-Oroz MC, et al. Movement-related changes in oscillatory activity in the human subthalamic nucleus: ipsilateral vs. contralateral movements. Eur J Neurosci 2005;22:2315-2324.
68. Tachibana Y, Kita H, Chiken S, et al. Motor cortical control of internal pallidal activity through glutamatergic and GABAergic inputs in awake monkeys. Eur J Neurosci 2008;27:238-253.
69. Aron AR, Poldrack RA. Cortical and subcortical contributions to stop signal response inhibition: role of the subthalamic nucleus. J Neurosci 2006;26:2424-2433.
70. Baunez C, Dias C, Cador M, Amalric M. The subthalamic nucleus exerts opposite control on cocaine and 'natural' rewards. Nat Neurosci 2005;8:484-489.
71. Frank MJ, Samanta J, Moustafa AA, Sherman SJ. Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science 2007;318:1309-1312.
72. Frank MJ. Hold your horses: a dynamic computational role for the subthalamic nucleus in decision making. Neural Netw 2006;19:1120-1136.
73. Funkiewiez A, Ardouin C, Caputo E, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:834-839.
74. Mallet L, Schupbach M, N'Diaye K, et al. Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior. Proc Natl Acad Sci USA 2007;104:10661-10666.
75. Purdon Martin J, Alcock NS. Hemichorea associated with a lesion of the corpus Luysii. Brain 1934;57:504-516.
76. Carpenter MB, Whittier JR, Mettler FA. Analysis of choreoid hyperkinesia in the rhesus monkey. J Comp Neurol 1950;92:293-322.
77. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000;23(suppl):8-19.
78. Guridi J, Herrero MT, Luquin MR, et al. Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. Brain 1996;119:1717-1727.
79. Trost M, Su S, Su P, et al. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage 2006;31:301-307.
80. Levy R, Hazrati LN, Herrero MT, et al. Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states. Neuroscience 1997;76:335-343.
81. Obeso JA, Rodríguez-Oroz MC, Rodríguez M, et al. Current problems in understanding the basal ganglia model for Parkinson's disease and levodopa-induced dyskinesias. Ann Neurol 2000;47(suppl 1):22-32.
82. Hassani OK, Mouroux M, Feger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 1996;72:105-115.
83. Orieux G, Francois C, Feger J, Hirsch EC. Consequences of dopaminergic denervation on the metabolic activity of the cortical neurons projecting to the subthalamic nucleus in the rat. J Neurosci 2002;22:8762-8770.
84. Kreiss DS, Anderson LA, Walters JR. Apomorphine and dopamine D(1) receptor agonists increase the firing rates of subthalamic nucleus neurons. Neuroscience 1996;72:863-876.
85. Breit S, Lessmann L, Unterbrink D, et al. Lesion of the pedunculopontine nucleus reverses hyperactivity of the subthalamic nucleus and substantia nigra pars reticulata in a 6-hydroxydopamine rat model. Eur J Neurosci 2006;24:2275-2282.
86. Smith Y. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and parkinsonian brains. Mov Disord 2008;23:708-715.
87. Obeso JA, Rodriguez-Oroz MC, Lanciego JL, Rodriguez M. How does Parkinson's disease begin? The role of compensatory mechanisms. Trends Neurosci 2004;27:125-127.
88. Sidibe M, Smith Y. Differential synaptic innervation of striatofugal neurones projecting to the internal or external segments of the globus pallidus by thalamic afferents in the squirrel monkey. J Comp Neurol 1996;365:445-465.
89. Castle M, Aymerich MS, Sanchez-Escobar C, et al. Thalamic innervation of the direct and indirect basal ganglia pathways in the rat: ipsi-and contralateral projections. J Comp Neurol 2005;483:143-153.
90. Tande D, Feger J, Hirsch EC, Francois C. Parafascicular nucleus projection to the extrastriatal basal ganglia in monkeys. Neuroreport 2006;17:277-280.
91. Orieux G, Francois C, Feger J, et al. Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease. Neuroscience 2000;97:79-88.
92. Aymerich MS, Barroso-Chinea P, Perez-Manso M, et al. Consequences of unilateral nigrostriatal denervation on the thalamostriatal pathway in rats. Eur J Neurosci 2006;23:2099-2108.
93. Bacci JJ, Kachidian P, Kerkerian-Le Goff L, Salin P. Intralaminar thalamic nuclei lesions: widespread impact on dopamine denervation-mediated cellular defects in the rat basal ganglia. J Neuropathol Exp Neurol 2004;63:20-31.
94. Lanciego JL, Rodriguez-Oroz MC, Blesa FJ, et al. Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys. Mov Disord 2008;23:708-715.
95. Mink JW. The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol 1996;50:381-425.
96. Turner RS, Anderson ME. Pallidopaminel discharge related to the kinematics of reaching movements in two dimensions. J Neurophysiol 1997;77:1051-1074.
97. Matsumura M, Tremblay L, Richard H, Filion M. Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum. Neuroscience 1995;65:59-70.
98. Turner RS, Anderson ME. Context-dependent modulation of movement-related discharge in the primate globus pallidus. J Neurosci 2005;25:2965-2976.
99. Smith Y, Bevan MD, Shink E, Bolam JP. Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience 1998;86:353-387.
100. Smith Y, Wichmann T, DeLong MR. Synaptic innervation of neurones in the internal pallidal segment by the subthalamic nucleus and the external pallidum in monkeys. J Comp Neurol 1994;343:297-318.
101. Billings LM, Marshall JF. Glutamic acid decarboxylase 67 mRNA regulation in two globus pallidus neuron populations by dopamine and the subthalamic nucleus. J Neurosci 2004;24:3094-3103.
102. Kita H, Tachibana Y, Nambu A, Chiken S. Balance of monosynaptic excitatory and disynaptic inhibitory responses of the globus pallidus induced after stimulation of the subthalamic nucleus in the monkey. J Neurosci 2005;25:8611-8619.
103. Parent A, Hazrati LN. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 1995;20:91-127.
104. Floran B, Floran L, Sierra A, Aceves J. D2 receptor-mediated inhibition of GABA release by endogenous dopamine in the rat globus pallidus. Neurosci Lett 1997;237:1-4.
105. Galvan A, Floran B, Erlij D, Aceves J. Intrapallidal dopamine restores motor deficits induced by 6-hydroxydopamine in the rat. J Neural Transm 2001;108:153-166.
106. Delfs JM, Anegawa NJ, Chesselet MF. Glutamate decarboxylase messenger RNA in rat pallidum: comparison of the effects of haloperidol, clozapine and combined haloperidol-scopolamine treatments. Neuroscience 1995;66:67-80.
107. Herrero MT, Levy R, Ruberg M, et al. Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum. Neurology 1996;47:219-224.
108. Filion M, Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991;547:142-151.
109. Benazzouz A, Boraud T, Feger J, et al. Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with L-Dopa treatment. Mov Disord 1996;11:627-632.
110. Bezard E, Boraud T, Bioulac B, Gross CE. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Eur J Neurosci 1999;11:2167-2170.
111. Soares J, Kliem MA, Betarbet R, et al. Role of external pallidal segment in primate parkinsonism: comparison of the effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced parkinsonism and lesions of the external pallidal segment. J Neurosci 2004;24:6417-6426.
112. Blandini F, Levandis G, Bazzini E, et al. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from and old model. Eur J Neurosci 2007;25:397-405.
113. Hassani OK, Mouroux M, Feger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 1996;72:105-115.
114. Mounayar S, Boulet S, Tande D, et al. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 2007;130:2898-2914.
115. Whone AL, Moore RY, Piccini PP, Brooks DJ. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol 2003;53:206-213.
116. Rubchinsky LL, Kopell N, Sigvardt KA. Modeling facilitation and inhibition of competing motor programs in basal ganglia subthalamic nucleus-pallidopaminel circuits. Proc Natl Acad Sci USA 2003;100:14427-14432.
117. Filion M, Tremblay L, Bedard PJ. Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys. Brain Res 1988;444:165-176.
118. Boraud T, Bezard E, Bioulac B, Gross CE. Ratio of inhibited-to-activated pallidal neurons decreases dramatically during passive limb movement in the MPTP-treated monkey. J Neurophysiol 2000;83:1760-1763.
119. Mena-Segovia J, Bolam JP, Magill PJ. Pedunculopontine nucleus and basal ganglia: distant relatives or part of the same family? Trends Neurosci 2004;27:585-588.
120. Takakusaki K, Saitoh K, Haradopamine H, Kashiwayanagi M. Role of basal ganglia-brainstem pathways in the control of motor behaviors. Neurosci Res 2004;50:137-151.
121. Inglis WL, Olmstead MC, Robbins TW. Selective deficits in attentional performance on the 5-choice serial reaction time task following pedunculopontine tegmental nucleus lesions. Behav Brain Res 2001;123:117-131.
122. Woolf NJ, Butcher LL. Cholinergic systems in the rat brain: III. Projections from the pontomesencephalic tegmentum to the thalamus, tectum, basal ganglia, and basal forebrain. Brain Res Bull 1986;16:603-637.
123. Bevan MD, Bolam JP. Cholinergic, GABAergic, and glutamate-enriched inputs from the mesopontine tegmentum to the subthalamic nucleus in the rat. J Neurosci 1995;15:7105-7120.
124. Hammond C, Rouzaire-Dubois B, Feger J, et al. Anatomical and electrophysiological studies on the reciprocal projections between the subthalamic nucleus and nucleus tegmenti pedunculopontinus in the rat. Neuroscience 1983;9:41-52.
125. Spann BM, Grofova I. Nigropedunculopontine projection in the rat: an anterograde tracing study with Phaseolus Vulgaris-leucoagglutinin (PHA-L). J Comp Neurol 1991;311:375-388.
126. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci USA 1987;84:5976-5980.
127. Gomez-Gallego M, Fernandez-Villalba E, Fernandez-Barreiro A, et al. Changes in the neuronal activity in the pedunculopontine nucleus in chronic MPTP-treated primates: an in situ hybridization study of cytochrome oxidopaminese subunit I, choline acetyl transferase, and substance P mRNA expression. J Neural Transm 2007;114:319-326.
128. Kojima J, Yamaji Y, Matsumura M, et al. Excitotoxic lesions of the pedunculopontine tegmental nucleus produce contralateral hemiparkinsonism in the monkey. Neurosci Lett 1997;226:111-114.
129. Mazzone P, Lozano A, Stanzione P, et al. Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson's disease. Neuroreport 2005;16:1877-1881.
130. Nandi D, Aziz TZ, Giladi N, et al. Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus. Brain 2002;125:2418-2430.
131. Jenkinson N, Nandi D, Miall RC, et al. Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey. Neuroreport 2004;15:2621-2624.
132. Stefani A, Lozano AM, Peppe A, et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain 2007;130:1596-1607.
133. Pierantozzi M, Palmieri MG, Galati S, et al. Pedunculopontine nucleus deep brain stimulation changes spinal cord excitability in Parkinson's disease patients. J Neural Transm 2008;115:731-735.
134. Leblois A, Boraud T, Meissner W, et al. Competition between feedback loops underlies normal and pathological dynamics in the basal ganglia. J Neurosci 2006;26:3567-3583.
135. Basso MA, Powers AS, Evinger C. An explanation for reflex blink hyperexcitability in Parkinson's disease. J Neurosci 1996;16:7308-7317.
136. Marden CD. The mysterious motor functions of the basal ganglia. Neurology 1982;32:514-539.
137. Bergman H, Wichmann T, Karmon B, DeLong MR. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 1994;72:507-520.
138. Dejean C, Gross CE, Bioulac B, Boraud T. Dynamic changes in the cortex-basal ganglia network after dopamine depletion. J Neurophysiol 2008;100:385-396.
139. Brown P. Oscillatory nature of human basal ganglia activity: relationship to the pathophysiology of Parkinson's disease. Mov Disord 2003;18:357-363.
140. Alonso-Frech F, Zamarbide I, Alegre M, et al. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease. Brain 2006;129:1748-1757.
141. Alegre M, Labarga A, Gurtubay IG, et al. Movement-related changes in cortical oscillatory activity in ballistic, sustained and negative movements. Exp Brain Res 2003;148:17-25.
142. Rodríguez MC, Guridi J, Mewes, et al. The subthalamic nucleus and tremor in Parkinson's disease. Mov Dis 1998;13(suppl 1):111-118.
143. Ohye C, Shibazaki T, Hirai T, et al. Tremor-mediating thalamic zone studied in humans and in monkeys. Stereotact Funct Neurosurg 1993;60:136-145.
144. Bevan MD, Magill PJ, Terman D, et al. Move to the rhythm: oscillations in the subthalamic nucleus-external globus pallidus network. Trends Neurosci 2002;25:525-531.
145. Garcia-Cabezas MA, Rico B, Sanchez-Gonzalez MA, Cavadopamine C. Distribution of the dopamine innervation in the macaque and human thalamus. Neuroimage 2007;34:965-984.
146. Rivlin-Etzion M, Marmor O, Saban G, et al. Low-pass filter properties of basal ganglia cortical muscle loops in the normal and MPTP primate model of parkinsonism. J Neurosci 2008;28:633-649.
147. Andrews CJ, Burke JD, Lance JW. The response to muscle stretch and shortening in parkinsonian rigidity. Brain 1972;95:795-812.
148. Rothwell JC, Obeso JA, Traub MM, Marsden CD. The behavior of the long-latency stretch reflex in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1983;46:35-44.
149. Reis J, Swayne OB, Vandermeeren Y, et al. Contribution of transcranial magnetic stimulation to the understanding of cortical mechanisms involved in motor control. J Physiol 2008;586:325-351.
150. Bezard E, Gross MC, Brotchie JM. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 2003;26:215-221.
151. Obeso JA, Rodriguez-Oroz M, Marin C, et al The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 2004;62(suppl 1):S17-S30.
152. Grace A. Physiology of the normal and dopamine-depleted basal ganglia: insights into L-DOPA pharmacotherapy. Mov Disord (in press).
153. Heimer G, Bar-Gad I, Goldberg JA, Bergman H. Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism. J Neurosci 2002;22:7850-7855.
154. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-687.
155. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Infusion of levodopa methyl ester in patients with advanced PD: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910.
156. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006;59:559-562.
157. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson's disease. Arch Neurol 2004;61:561-566.
158. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
159. Marin C, Aguilar E, Mengod G, et al. Concomitant short-and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study. Eur J Neurosci 2007;25:259-269.
160. Nambu A. A new dynamic model of the cortico-basal ganglia loop. Prog Brain Res 2004;143:461-467
161. Obeso JA, Rodriguez-Oroz MC, Blesa J, Guridi G. The globus pallidus pars externa and Parkinson's disease: ready for prime time? Exp Neurol 2006;202:1-7.
162. Brown P, Eusebio A. Paradoxes of functional neurosurgery: clues from basal ganglia recording. Mov Disord 2008;23:12-20.